Projekt

Comparison of ATG-Fresenius S to Thymoglobulin in prophylaxis for immunological high risk patients following renal transplantion

Abgeschlossen · 2009 bis 2010

Art
Klinische Forschung
Reichweite
Multizentrisch, KSSG als teilnehmendes Zentrum
Bereiche
Status
Abgeschlossen
Start
2009
Ende
2010
Finanzierungsart
Eigenfinanzierung
Studiendesign
Open, multicenter, randomised, parallel group pilot study
Schlagwörter (Tags)
ATG-Fresenius, Thymoglobulin, Inductionstherapie
Projektpartner
Universitätsspital Basel
Kurzbeschreibung/Zielsetzung

Two poyclonal depleting antibody products as an immunosuppresive induction therapy will be compared regarding safety profile and efficacy in immunological high risk patients after renal transplantion.

1. a regimen consisting of a triple drug therapy with Tacrolimus, MMF, and steroids as basis therapy plus IVIG for 5 days (total dose 2g/kg bw. max. 140g). in addition, the patients receive intra-operative 9 mg/kg bw.ATG-Fresenius S (completed before reperfusion), followed by 3 mg/kg bw/d for the next 4 consecutive days.

2. a regimen consisting of a triple drug therapy with Tacrolimus, MMF, and steroids as basis therapy plus IVIG for 5 days (total dose 2g/kg bw. max. 140g). in addition, the patients receive intra-operative 1.5 mg/kg bw Thymoglobulin (completed before reperfusion), followed by 1.5mg/kg bw/d for the next 3 consecutive days.